NantHealth & NantOmics to Present Data on Tumor Mutation Burden (TMB) & PD-L1 Expression in SDH/FH Mutated Solid Tumors at th...
June 03 2019 - 9:04AM
Business Wire
Results to be presented during the cancer
prevention, hereditary genetics and epidemiology session at the
ASCO 2019 Annual Meeting
NantWorks, LLC today announced that its affiliate companies,
NantHealth, Inc., (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company, and NantOmics,
LLC, the leader in molecular analyses , will present data on the
association between increased TMB and increased PD-L1 expression
with the presence of SDH/FH mutations in a variety of tumors, using
3,461 paired tumor/normal whole exome sequences from the NantHealth
clinical cases database to look into the potential therapeutic role
for inhibition of PD-1/PD-L1 pathway in these tumors during the
cancer prevention, hereditary genetics and epidemiology session at
the ASCO 2019 Annual Meeting, an event bringing together more than
32,000 global oncology professionals from May 31-June 4, 2019 at
McCormick Place in Chicago, Illinois. NantHealth and NantOmics
conducted this study with researchers from Virginia Commonwealth
University’s Massey Cancer Center. NantWorks will be exhibiting at
booth #24080 during the event.
“We believe the data from our retrospective analysis may impact
the use of immunotherapy for SDH/FH deficient tumors,” said Sandeep
“Bobby” Reddy, MD, Chief Medical Officer, NantHealth. “Our analysis
provides actionable insight and evidence-based support to further
our mission of optimizing patient outcomes and enabling value-based
care, specifically in the oncology realm.”
Presentation Details
Tumor mutation burden and PD-L1 expression in SDH/FH mutated
solid tumors, Abstract #1524WHO: NantHealth, Inc.
and NantOmics, LLCWHAT: Cancer Prevention, Hereditary
Genetics and Epidemiology SessionWHEN: June 3, 1:15-4:15 PM
CDTWHERE: Hall A, McCormick Place
Presentation Summary
Succinate Dehydrogenases and Fumarate Hydratase (SDH/FH)
deficient tumors are characterized by succinate/fumarate
accumulation and resultant pseudohypoxia that drives malignant
transformation. It has been recently shown that HIF-1a
stabilization due to hypoxia can lead to upregulation of PD-1
ligand. This study explored tumor mutation burden (TMB), gene
expression of PD-L1 and expression of other immune
checkpoint-associated genes in a diverse cohort of human tumors
harboring SDH A, B, C, D and FH mutations. Retrospective analysis
was performed on 3,461 paired tumor/normal whole exome sequences
(WES; ~150x coverage) from the NantHealth clinical cases database.
42 clinical cases with potentially pathogenic variants (pPV) in
SDHx and FH were identified. Variant pathogenicity was assessed by
multiple factors including driver gene status, variant class (e.g.
Missense), PhastCons conservation score and population allele
frequency. The study found an association between increased TMB and
increased PD-L1 expression with the presence of SDH/FH mutations in
a variety of tumors. These key parameters imply that a higher TMB
may drive the evolutionary pressure to select clones with a PD-L1
high phenotype. This observation supports a potential therapeutic
role for inhibition of PD-1/PD-L1 pathway in these tumors.
About NantHealth:
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payers, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting edge data and technology
towards the goal of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in molecular analysis (GPS
Cancer® and Liquid GPS®), payer/provider platforms that exchange
information in near-real time (NaviNet and Eviti), and connected
care solutions that deliver Medical Device Interoperability (MDI).
NantHealth’s GPS Cancer® molecular profiling provides comprehensive
DNA & RNA tumor-normal profiling combined with pharmacogenomics
analysis. Liquid GPS® provides non-invasive testing of cfDNA and
cfRNA to monitor cancer mutations and potentially select targeted
therapies, chemotherapies, and immunotherapies. For more
information, please visit www.nanthealth.com.
About NantOmics:
NantOmics, a member of the NantWorks ecosystem of companies,
invented and developed the technologies that drive NantHealth’s GPS
Cancer® platform. GPS Cancer® provides actionable intelligence and
molecularly driven decision support for cancer patients and their
providers at the point of care. NantOmics is the first molecular
analysis company to pioneer an integrated approach to unearthing
molecular variances and profiles that initiate and drive cancer, by
analyzing both normal and tumor cells from the same patient and
following identified variances from DNA to RNA to protein to drug.
Having pioneered tumor-normal DNA sequencing and introduced whole
RNA transcriptomic analysis to better inform clinical treatment
decisions, NantOmics has provided molecular insights for thousands
of cancer patients.
NantOmics has a highly scalable cloud-based infrastructure
capable of storing and processing thousands of genomes a day,
computing genomic variances in near real-time and correlating
proteomic pathway analysis with quantitative gene expression and
pharmacogenomic signatures, which guides the use of
immunotherapies, chemotherapies and targeted therapies. Clinical
studies for neoepitope vaccines using NantOmics’ proprietary
technologies and novel artificial intelligence platforms are
currently underway. For more information please visit
www.nantomics.com.
About VCU and VCU Health
Virginia Commonwealth University is a major, urban public
research university with national and international rankings in
sponsored research. Located in downtown Richmond, VCU enrolls more
than 31,000 students in 217 degree and certificate programs in the
arts, sciences and humanities. Thirty-eight of the programs are
unique in Virginia, many of them crossing the disciplines of VCU’s
11 schools and three colleges. The VCU Health brand represents the
VCU health sciences academic programs, the VCU Massey Cancer Center
and the VCU Health System, which comprises VCU Medical Center (the
only academic medical center and Level I trauma center in the
region), Community Memorial Hospital, Children’s Hospital of
Richmond at VCU, MCV Physicians and Virginia Premier Health Plan.
For more, please visit www.vcu.edu and www.vcuhealth.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190603005490/en/
MEDIA CONTACTNANTJen
HodsonJen@nant.com562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Aug 2024 to Sep 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Sep 2023 to Sep 2024